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survival among the patients with 1-3 brain metastases from 
non-small cell lung cancer. 
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Purpose or Objective: To know the failure patterns and 
survival of T4N0-1 non-small cell lung cancer (NSCLC) treated 
with definitive radiotherapy. 
 
Material and Methods: Ninety five patients with T4N0-1 
NSCLC who received definitive radiotherapy with or without 
chemotherapy from May 2003 to Oct 2014 were 
retrospectively reviewed. Standard radiotherapy scheme was 
66 Gy in 30 fractions. Main concurrent chemotherapy regimen 
was weekly Paclitaxel 50 mg/m2 combined with Cisplatin 20 
mg/m2 or Carboplatin AUC 2. Primary outcome was overall 
survival (OS). Secondary outcomes were failure patterns and 
toxicities. 
 
Results: The median age was 64 (range, 34-90). Eighty eight 
percent (n=84) of patients had ECOG performance status 0-1 
and 42% (n=40) experienced pretreatment weight loss. Sixty 
percent (n=57) of patients had no metastatic regional lymph 
nodes. The median radiation dose was EQD2 67.1 Gy (range, 
56.9-83.3). Seventy one patients (75%) were treated with 
concurrent chemotherapy. Among them, 13 patients were 
also administered neoadjuvant chemotherapy. At the median 
follow-up of 21 months (range, 1-102), 3-year OS was 44%. 
Three-year cumulative incidence of local recurrence and 
distant recurrence were 48.8% and 36.3%. Pretreatment 
weight loss and combination of chemotherapy were 
significant factors in OS. Acute esophagitis over grade 3 was 
occurred in 3 patients and only one grade 3 chronic 
esophagitis was reported. There was no grade 3-4 radiation 
pneumonitis. 
 
Conclusion: Definitive radiotherapy for T4N0-1 NSCLC 
resulted in favorable survival with acceptable toxicity rates 
and local recurrence was a major pattern of recurrence. For 
improving local tumor control, the application of intensity 
modulated radiotherapy and radio-sensitizing agents would 
be needed. 
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Purpose or Objective: Stereotactic Body Radiation Therapy 
has become one of the standard treatments in Stage I NSCLC. 
However, there exists the problem of reoxygenation for large 
tumors and BED for serial organs locating near the central 
lung. Therefore, we have been treating especially these 
cases by decreasing the fraction dose while increasing overall 
treatment time and total dose (so-called hypofractionated 3-
dimensional noncoplanar conformal radiation therapy). To 
clarify the prognostic factors of this treatment method, we 
carried out this investigation. 
 
Material and Methods: Eligibility criteria were as follows: 
maximum tumor diameter not greater than 5cm, PS between 
0 and 2, and no limitation regarding age and pulmonary 
function. Radiotherapy was given with 6MV photon beam by 
fixed 10 non-coplanar conformal beams to a total dose of 
75Gy in 25 fractions in 5 weeks. Irradiation was aiming at the 
ITV with proper margins. No ENI was given. Between Jan. 
2002 and Jan. 2011, 109 eligible cases were treated. Age 
ranged from 53 to 93 (median 78). The male/female ratio 
was 79/30. There were 100 PS 1 and 9 PS 2 cases. There were 
22 low risk operable cases, 31 high risk operable cases 
(surgeons recommended RT), and 56 inoperable cases. There 
were 63 T1 tumors and 46 T2. Forty-six cases were central 
tumors and the other 63 were peripheral tumors. Seventy 
tumors were adenocarcinoma, 23 tumors were squamous cell 
carcinoma, and 16 others. Regarding tumor markers, 
pretreatment CEA was elevated (>5ng/ml) in 36 cases. Using 
these 8 parameters, multivariate analysis (MVA) for overall 
survival (OS) and local control (LC) was performed by Cox’s 
Proportional Hazard Model. Median follow-up period was 67 
months. 
 
Results: Five-year LC and OS rates were 84% and 50%, 
respectively. As for LC, MVA revealed that histology 
(p=0.0279) was prognostic and PS (p=0.0541) and 
pretreatment CEA (p=0.0560) had a tendency. As for OS, MVA 
revealed that gender (p=0.0081) and pretreatment CEA 
(p=0.0189) were prognostic and operability (p=0.0520) and 
histology (p=0.0913) had a tendency. On the other hand, age, 
T-stage or tumor location was not prognostic regarding 
neither LC nor OS. 
 
Conclusion: Our overall results of this method were 
promising considering the status of the patients. Regarding 
LC, adenocarcinomas were better controlled compared with 
other histologies, and patients with good PS and tumors with 
normal pretreatment CEA tended to be better controlled. 
Regarding OS, female patients, patients with normal 
pretreatment CEA survived better than their counterpart, 
and operable cases and adenocarcinoma cases tended to 
survive better than their counterpart, respectively. Unlike 
other reported series, T2 stage and central tumors did not 
carry worse prognoses with this treatment method. 
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Purpose or Objective: Stereotactic ablative radiotherapy 
(SABR) is an internationally accepted standard of care in the 
management of early stage medically inoperable NSCLC [1]. 
However, the issue of whether the excellent results of SABR 
for lung cancer can also be achieved when patients are 
treated outside pioneering academic institutions remains a 
pertinent one [2] 
South Tees NHS Trust is a large general hospital with a non-
academic cancer centre, serving a population of 1.1 million 
in the North-East of England. In 2009, we became the first 
non-academic cancer centre in the UK to establish a SABR 
programme. To date, over 200 patients have been treated 
with SABR. 
We present outcome data of 167 patients with Stage IA-IIB 
lung cancer, all of whom have at least 6 months of follow up 
and CT assessment of response. 
 
Material and Methods: Data was collected prospectively 
between Sept 2009 – Sept 2015. Only patients with stage IA-
IIB histologically proven NSCLC or PET +ve growing lesions, 
and at least 6 months of follow up, were included in the 
analysis. All patients were treated according to local 
protocols based on the national guidelines of the UK SABR 
Consortium.The following risk adapted treatment schedules 
were used depending on size and location of the tumour: 
54Gy in 3 fractions (40patients), 55Gy in 5 fractions (105pts), 
60Gy in 8 fractions (15pts), or 50Gy in 10 fractions (7pts) 
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Follow up was with CXR at 6months followed by CT at 6 
months and clinical follow up, 3 monthly. 
 
Results: 167 patients with stage IA-IIB disease treated. 55% 
histologically proven.There were 4 (2.4%) radiologically 
confirmed local recurrences giving a local control rate of 
97.6%. Median survival was 43.2months. 3 year Overall 
Survival was 56.4% (see Fig 1). Treatment was well tolerated 
with minimal G3 toxicity (5 patients). 
 
Conclusion: Our results suggest that SABR for medically 
inoperable NSCLC can be safely and effectively implemented 
in a non-academic institution with appropriate equipment 
and training.Clinical outcomes are comparable with 
internationally published series [3}, with encouraging 3yr OS 
rate of 56%. Toxicity is minimal. Longer term follow-up is 
required to confirm findings and provide data regarding long-
term toxicity. 
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Purpose or Objective: In patients with inoperable stage I 
non-small cell lung cancer (NSCLC) or for those refusing 
surgery, stereotactic body radiotherapy and particle 
radiotherapy have become therapeutic options. We 
conducted a Phase I/II study on single-fraction carbon ion 
radiotherapy (SF-CIRT) for stage I NSCLC that yielded a 3-year 
survival rate of 75.5% for 218 patients. Until now, the effect 
of hypofractionated CIRT on pulmonary function (PF) has not 
been well documented. The purpose of this study was to 
assess the long-term impact of SF-CIRT on PF in stage I NSCLC 
patients. 
 
Material and Methods: A review of prospectively collected 
data from SF-CIRT-treated patients was performed. Patients 
underwent PF tests (PFT) (or: underwent a PF test) 
immediately before, and at 6, 12, and 24 months after 
irradiation. Patients who relapsed or needed adjuvant 
treatment were excluded as these events might affect PF.  
 
Results:  
 
 
Forty patients treated between 2007 and 2012 fulfilled the 
inclusion criteria. According to the dose escalation study 
protocol, a median prescribed single-fraction dose of 46 GyE 
(range, 44-50 GyE) was delivered. All treatment-related 
complications were self-limited, without any grade 3-5 
toxicities. Two years post-CIRT, the mean values of forced 
expiratory volume in 1 sec (FEV1) [-8.4% ± 11.9% (p < 0.001)] 
and the FEV1 per unit of forced vital capacity (FEV1/FVC) [-
8.9% ± 11.7% (p < 0.001)] were less than the pre-CIRT values. 
There were no significant overall changes in total lung 
capacity, vital capacity, FVC, and residual volume before SF-
CIRT and 2 years after SF-CIRT. At 6 months post-treatment, 
the diffusion capacity of the lung for carbon monoxide 
(DLCO) was significantly less than the pretreatment value 
(86.7 ± 32.7% vs. 78.1 ± 31.1%; p = 0.002); however, at 24 
months post-treatment, the mean DLCO recovered to 
pretreatment levels (86.9 ± 30.5%). This might have been due 
to recovery from non-symptomatic radiation pneumonitis 
and/or smoking cessation. 
 
 
 
Conclusion: We found stage I NSCLC patients had good long-
term preservation of PF after SF-CIRT. Follow-up PFT 
revealed the following: Declines in FEV1 and FEV1/FVC were 
statistically significant but clinically trivial, DLCO decreased 
temporary, thereafter it tended to recover to pretreatment 
levels within 2 years. 
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Purpose or Objective: An evaluation of thymic tumors 
patient radiotherapy results.  
 
Material and Methods: 93 patients (54F [58%], 39M [42%]) 
aged from 3 (6 children) to 77 (median 48) treated for thymic 
tumors since 1981. 84 patients (90%) were diagnosed with 
thymoma, 9 (10%) with thymic carcinoma. Masaoka stage was 
assessed in 93% (56% stage II, 31%-III, 6%- IV). All patients 
were irradiated. In 76 cases radiotherapy (RT) followed 
surgery – in 41 patients after radical and in 35 after 
incomplete resection. In 17 cases RT was definitive 
treatment, combined in 14 patients with chemotherapy. 
Patients were irradiated with fraction dose of 1.1-4.0Gy 
(median 2.0) to the total dose of 20-68Gy (median 49.5). 
Patient- and treatment-related factors potentially affecting 
survival and local control (LC) were evaluated with log-rank 
test. Survival analysis was performed with Kaplan-Meier 
method. 
 
Results: Tumors relapsed in 17 patients. Metastases occurred 
after 6-129months (median 10.1) in 12 patients (in 8 in 
lungs). During the follow-up 17 patients died due to 
progression(13) or recurrence(4) of the disease. Median 
overall survival (OS) in the whole group (since diagnosis) was 
140.2months. OS was significantly longer in patients with 
WHO B1 type(p=0.02), in good performance status 
(PS)(p=0.0005), without radiation-induced pulmonary 
fibrosis(p=0.02) or second cancer(p=0.03). Difference in OS 
between patients treated with radical surgery+RT, non-
radical surgery+RT and definitive RT was of borderline 
significance(p=0.065). Factors significantly decreasing LC 
were: male sex(p=0.04), WHO B2 type(p=0.01), bad 
PS(p=0.0007), presence of metastases(p=0.003) and second 
cancer(p=0.03).  
 
